Back HIV/HBV Coinfection

HIV/HBV Coinfection

AASLD Liver Meeting Starts this Weekend in Washington, DC

The American Association for the Study of Liver Diseases (AASLD) annual Liver Meeting gets underway this Friday, running November 1-5 at the Walter E. Washington Convention Center in Washington, DC. The highlight of this year's meeting will be numerous presentations on next-generation direct-acting antivirals (DAAs) for hepatitis C, now in late stages of development, both as interferon add-ons and in interferon-free regimens.

alt

Read more:

Coverage of the 2013 AASLD Liver Meeting

HIVandHepatitis.com coverage of the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2013) in Washington, DC, November 1-5, 2013.

Conference highlights include treatment for hepatitis B and C, new direct-acting HCV drugs, interferon-free hepatitis C therapy, management of liver disease complications, HIV/HBV and HIV/HCV coinfection, and prevention and treatment of hepatocellular carcioma.

Full listing by topic

10/30/13

alt

Tenofovir Is Highly Effective for HIV/HBV Coinfection, Meta-analysis Shows

Tenofovir, which has potent activity against both HIV and hepatitis B virus (HBV), is the most effective hepatitis B treatment for HIV/HBV coinfected people, according to a 23-study meta-analysis described in the July 10, 2013, issue of the open-access journal PLoS One. Combining it with emtricitabine did not improve hepatitis B response.

alt

Read more:

ICAAC 2013: Liver Cancer Often Diagnosed Late with Poor Survival in People with HIV

Hepatocellular carcinoma (HCC) is frequently diagnosed at an advanced stage in HIV positive people with hepatitis B or C coinfection, contributing to a high mortality rate that has changed little in recent years, according to a report at the recent 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013) in Denver.

alt

Read more:

IAS 2013: People with HBV or HCV Coinfection May Not Respond as Well to HIV Treatment

HIV positive people with hepatitis B or C coinfection in Asia had lower CD4 T-cell counts, saw smaller CD4 cell gains after starting antiretroviral therapy, and had a higher risk of death, researchers reported at the recent 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) in Kuala Lumpur.

alt

Read more: